N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H1 2016

This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.

Global Markets Direct’s, ‘N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H1 2016’, provides in depth analysis on N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted pipeline therapeutics.

The report provides comprehensive information on the N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
• The report reviews N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics and enlists all their major and minor projects
• The report assesses N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) Overview 6
Therapeutics Development 7
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Stage of Development 7
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Therapy Area 8
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Indication 9
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Products Glance 10
Early Stage Products 10
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Companies 11
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Universities/Institutes 13
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Molecule Type 18
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Companies Involved in Therapeutics Development 20
Bristol-Myers Squibb Company 20
CohBar, Inc. 21
Polyphor Ltd. 22
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Drug Profiles 23
Drugs to Agonize FPR-2 for Inflammation - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Humanin - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
NCP-70X - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Peptides for Alzheimer''s Disease and Type II Diabetes - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischemia - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Synthetic Peptides to Agonize FPR1/2 for Immunology and Infectious Disease - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Synthetic Peptides to Antagonize FPR1/2 for Immunology and Infectious Disease - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Dormant Projects 31
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Discontinued Products 32
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Featured News & Press Releases 33
May 18, 2012: New drug discovery collaborations with Queen Mary University of London launched 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Molecule Type, H1 2016 19
Pipeline by Bristol-Myers Squibb Company, H1 2016 20
Pipeline by CohBar, Inc., H1 2016 21
Pipeline by Polyphor Ltd., H1 2016 22
Dormant Projects, H1 2016 31
Discontinued Products, H1 2016 32

List of Figures

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Top 10 Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 10
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Mechanism of Actions, H1 2016 16
Number of Products by Stage and Mechanism of Actions, H1 2016 16
Number of Products by Molecule Types, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 18